

## Bulletin from annual general meeting in Prostatype Genomics AB (publ)

**The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the "Company") was held on 15 May 2025. Below is a summary of the decisions that were made. All decisions were made unanimously.**

### **Annual report and results**

The annual general meeting adopted the income statement and the balance sheet for the financial year 2024 and resolved, in accordance with the board of directors' proposal, that the result according to the approved income statement should be transferred to a new account. No dividends are to be paid.

### **Discharge from liability**

The annual general meeting granted the board of directors as well as the managing director discharge from liability for the management of the Company's business for the financial year 2024.

### **Number of board members and board deputies**

The annual general meeting decided that the board shall consist of five (5) board members, without deputy directors.

### **Remuneration to the board of directors and the auditor**

The annual general meeting decided that a board fee of SEK 160,000 shall be paid to the chairperson and SEK 80,000 to each other member of the board, unless the member in question is prevented from receiving such a fee due to current guidelines of the member's employer. Compensation to the auditor shall be paid as per approved invoice.

### **Election of the board of directors**

The annual general meeting decided to re-elect Anders Lundberg, Michael Häggman, Mattias Prage, Håkan Englund and Jörgen Dahlström as ordinary members for the time until the next annual general meeting. Johan Waldhe was not re-elected, as he had declared that he was not available for re-election. The annual general meeting decided to re-elect Anders Lundberg as chairperson of the board.

### **Election of auditor/auditing company**

The annual general meeting decided to re-elect the registered auditing company Grant Thornton Sweden AB, with Joakim Söderin as chief auditor, for the time until the next annual general meeting.

### **Resolution on nomination committee**

The AGM resolved that the Company, prior to the 2026 AGM, shall have a nomination committee that shall submit proposals for, among other things, board directors, board fees and auditor. The members of the nomination committee are appointed by the chairman of the board contacting the three largest shareholders in the company in terms of votes according to Euroclear's latest printout of the share register, who each appoint a member of the nomination committee.

**Amendment of the articles of association and new issue of units with preferential rights for existing shareholders**

The annual general meeting resolved, in order to enable the new issue of units, to amend the articles of association in accordance with the board's proposal, meaning that the limits in the articles of association for share capital are changed from the current minimum of SEK 500,000 and maximum of SEK 2,000,000 to a minimum of 2,500,000 and a maximum of 10,000,000 and that the limits for shares are changed from the current minimum of 5,000,000 and maximum of 20,000,000 to a minimum of 25,000,000 and a maximum of 100,000,000.

The annual general meeting also resolved to approve the board's resolution on 15 April 2025 regarding new issue of units with preferential rights for existing shareholders. Through the new issue, the Company's share capital can increase by a maximum of SEK 4,784,649.10 by issuing a maximum of 6,835,213 units. Each unit consists of four (4) shares and three (3) warrants of series TO 5, meaning that a maximum of 27,340,852 new shares and a maximum of 20,505,639 new warrants of series TO 5 can be issued.

**Authorization regarding so-called over-allotment**

The annual general meeting resolved to authorize the board of directors to, on one or more occasions during the period until 30 July 2025, resolve to issue of shares and/or warrants (units) through so-called over-allotment, which may be used in the event of oversubscription in the preferential rights issue of units. With support of the authorization, not more than 1,025,282 units may be issued, which corresponds to approximately 15 percent of the total amount of units which can be issued in the preferential rights issue of units. A rights issue in accordance with this authorization shall be made on terms corresponding to the terms of the preferential rights issue of units. Such an issue will be made with deviation from the shareholders' preferential rights and with the condition that payment may be made by set-off.

**Authorization regarding issue to guarantors**

The annual general meeting resolved to authorize the board of directors to, in connection with the general meeting's approval of the board of directors' resolution on the preferential rights issue of units, on one or more occasions during the time leading up to the next annual general meeting, resolve to increase the Company's share capital within the limits of the articles of association by issuing shares and/or warrants (units). The authorization may only be used to issue units to those who acted as guarantors in the preferential rights issue of units. If the board of directors utilizes the authorization, it may therefore be done with a deviation from the shareholders' pre-emptive right and with the condition that payment may be made by set-off.

**Incentive program 2025/2029**

The annual general meeting decided (A) on the implementation of an employee stock option program (Program 2025/2029) intended for employees and key persons in the Company or the Company's group, (B) on a directed issue of warrants to the Company to ensure the Company's delivery of shares under the Program and to cover any cash flow effects due to social costs in connection with the Program and (C) on approval of transfer of warrants or shares in the Company to participants in the Program.

The program shall include not more than 5,000,000 employee stock options. Employee stock options shall be offered and allocated free of charge based on the participants' competence, merits, performance, importance to the Company and the participant's individual fixed remuneration. The options may also be granted to employees and key persons employed in the United States. Allocation of stock options is decided no later than 31st of October 2025. Participants may exercise granted and vested stock options during the period from 1st of November 2028 up to and including 1st of May 2029. Certain strategic and operational targets may be set for the exercise of the stock options. Each employee stock option shall entitle the participant to acquire one (1) new share in the Company at an exercise price corresponding to 125 percent of the volume-weighted average price of the Company's share on Nasdaq First North Stockholm during a period of ten (10) trading days prior to the general meeting on 15 May 2025. The maximum dilution effect of the Program is estimated to amount to approximately ten (10) percent, provided that all options granted under the Program are exercised in full.

**General authorization to issue shares**

The annual general meeting resolved to authorize the board of directors to, on one or more occasions during the period up to the next annual general meeting of shareholders, resolve to issue shares, warrants and/or convertible loans (or combinations thereof, so-called units). If the board of directors uses the authorization, it may also be done with a deviation from the shareholders' pre-emptive right and/or with provisions regarding in-kind or set-off. An issue of securities in accordance with this authorization shall be made on market terms. The board of directors shall have the right to determine the terms and conditions regarding issues under this authorization and what persons shall be entitled to subscribe for issued securities.

**For more information about the Company, please contact:**

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

E-mail: [fredrik.rickman@prostatypegenomics.com](mailto:fredrik.rickman@prostatypegenomics.com)

**Certified Adviser**

DNB Carnegie Investment Bank AB

Telephone: +46 (0)73 856 42 65

E-mail: [certifiedadviser@carnegie.se](mailto:certifiedadviser@carnegie.se)

**About Prostatype Genomics**

Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB. The Company's Certified Adviser is Carnegie Investment Bank AB.